Full Press Release Details
| CONTACTS: | Warren Lancaster | |||
| 1-203-966-2556 (USA) | ||||
| warren.lancaster@marshalledwardsinc.com |
1 202 547-2880 (USA)
MARSHALL EDWARDS APPOINTS CEO AS A NEW DIRECTOR
Sydney, Australia and San Diego, CA May 6, 2010 Marshall Edwards, Inc.
(NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer
therapeutics, announced that Daniel Gold, Ph.D., the Company s President and Chief Executive
Officer, has been appointed to serve on the Board of Directors of the Company effective April 30,
2010. Dr. Gold will serve as a member of the Board of Directors until the 2010 annual meeting of
the stockholders, at which time he will stand for re-election.
Dr. Gold has more than 25 years of drug discovery and development experience. Most recently, he
was President and CEO of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure
at Prospect, Dr. Gold was founder and Chief Scientific Officer at Favrille, Inc., where he was an
integral member of a team that raised more than $200 million, including an IPO in 2005, and
advanced that company s lead oncology candidate through a pivotal Phase III clinical trial.
Dr. Gold s academic qualifications include Postdoctoral Fellowships at the
Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of
Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts
University, Boston and a B.A. in Biology from the University of California Los Angeles.
About Marshall Edwards, Inc.
Marshall Edwards, Inc. is a specialist oncology company focused on the clinical development of
novel anti-cancer therapeutics. These derive from a flavonoid technology platform, which has
generated a number of novel compounds characterized by broad ranging activity against a range of
cancer cell types with few side effects. The combination of anti-tumor cell activity and low
toxicity is believed to be a result of the ability of these compounds to target an enzyme present
in the cell membrane of cancer cells, thereby inhibiting the production of pro-survival proteins
within the cell. Marshall Edwards has licensed rights from Novogen Limited (ASX: NRT NASDAQ: NVGN)
to bring four oncology drugs phenoxodiol, triphendiol,
NV-143 and NV-128 to market globally.
Marshall Edwards is majority owned by Novogen Limited, an Australian biotechnology company that is
specializing in the development of therapeutics based on a flavonoid technology platform. Novogen
is developing a range of therapeutics across the fields of oncology, cardiovascular disease and
inflammatory diseases. More information on
phenoxodiol and on the Novogen group of companies can be found at www.marshalledwardsinc.com and www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials
and approved by the FDA as being safe and effective for the intended use. Statements included in
this press release that are not historical in nature are forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
You should be aware that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management s current expectations and are subject to
a number of risks and uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products; competitive factors; our
inability to protect our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to operate our business
without infringing the patents and proprietary rights of others; general economic conditions; the
failure of any products to gain market acceptance; our inability to obtain any additional required
financing; technological changes; government regulation; changes in industry practice; and one-time
events. We do not intend to update any of these factors or to publicly announce the results of any
revisions to these forward-looking statements.